The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function
Open accessAbstract
Background & Aims: Renal clearance is the major elimination pathway for sofosbuvir (SOF). We assessed the safety and efficacy of SOF‐containing regimens in patients with varying baseline estimated glomerular filtration rate (eGFR). Methods: HCV‐TARGET database is a multicentre, longitudinal ‘real‐world’ treatment cohort. Results: A total of 1789 patients [genotypes 1 (72%), 2 (17%) 3 (9%), 4–6 (2%)] had baseline eGFR determination: 73 with eGFR≤45 (18 with eGFR≤30, 5 on dialysis) were compared to 1716 with eGFR>45 ml/min/1.73 m 2. Patients with baseline eGFR≤45 vs. >45 differed in being female (55% vs. 36%), age ≥65 years (24% vs. 16%), Black race (22% vs. 12%), having cirrhosis with decompensation (73% vs. 24%) and being post‐transplant (49% vs. 10%), all P < 0.05. All patients with eGFR≤45 were treated with SOF 400 mg/day (including those on haemodialysis) and had median starting ribavirin (RBV) dose of 800 mg (IQR: 400–1200). Sustained virologic response (SVR) frequencies were similar across eGFR groups, ranging from 82–83%. Patients with eGFR ≤45 more frequently experienced anaemia, worsening renal function and serious AE s (all P < 0.05), and these associations persisted when limiting analysis to RBV‐free regimens. Patients with baseline eGFR≤30 and eGFR 31–45 had similar frequencies of efficacy and safety outcomes. Conclusions: Sustained viral clearance was achieved in 83% of patients with renal impairment (eGFR ≤45 ml/min/1.73 m 2) treated with SOF‐containing regimens. However, these patients had higher rates of anaemia, worsening renal dysfunction and serious adverse events regardless of use of RBV. Patient with renal impairment require close monitoring and should be treated by providers extensively experienced with SOF‐containing regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
A wilcoxon‐type test for trend
Cuzick, J. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040112 · Cited by 1,900
Panel, A. H. G. (2015) · Hepatology · doi:10.1002/hep.27950 · Cited by 1,382
Nelson, D. R., Cooper, J. N., Lalezari, J. P., Lawitz, E., Pockros, P. J., Gitlin, N., Freilich, B. F., Younes, Z. H., Harlan, W., Ghalib, R., et al. (2015) · Hepatology · doi:10.1002/hep.27726 · Cited by 689
Self-citationAcute kidney injury in cirrhosis
Garcia-Tsao, G., Parikh, C. R., & Viola, A. (2008) · Hepatology · doi:10.1002/hep.22605 · Cited by 662
Hézode, C., Fontaine, H., Dorival, C., Larrey, D. G., Zoulim, F., Canva, V., de Lédinghen, V., Poynard, T., Samuel, D., Bourlière, M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.035 · Cited by 443
Effects of ribavirin on red blood cells
Canonico, P. G., Kastello, M. D., Spears, C. T., Brown, J. R., Jackson, E. A., & Jenkins, D. E. (1984) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(84)90138-8 · Cited by 79
Karino, Y., Ozeki, I., Hige, S., Kimura, M., Arakawa, T., Nakajima, T., Kuwata, Y., Sato, T., Ohmura, T., & TOYOTA, J. (2013) · Journal of Viral Hepatitis · doi:10.1111/jvh.12162 · Cited by 41
Cited by
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
EASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
EASL Recommendations on Treatment of Hepatitis C 2016
(2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.001 · Cited by 985
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
Gane, E., Lawitz, E., Pugatch, D., Papatheodoridis, G., Bräu, N., Brown, A., Pol, S., Leroy, V., Persico, M., Moreno, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704053 · Cited by 400
Self-citation
Metadata
- Authors
- Saxena, V., Koraishy, F. M., Sise, M. E., Lim, J. K., Schmidt, M., Chung, R. T., Liapakis, A., Nelson, D. R., Fried, M. W., Terrault, N. A., & HCV‐TARGET
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2016-03-24
- Volume
- 36
- Issue
- 6
- Pages
- 807-816
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2284028703
- Cited by
- 300
- References
- 8
- FWCI
- 42.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function. https://app.cochat.ai/papers/10.1111/liv.13102
- The paper
- Saxena, V., Koraishy, F. M., Sise, M. E., Lim, J. K., Schmidt, M., Chung, R. T., Liapakis, A., Nelson, D. R., Fried, M. W., Terrault, N. A., & HCV‐TARGET. (2016). Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function. Liver International. https://doi.org/10.1111/liv.13102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.